Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has achieved an objective response at 12 months of treatment with PD-1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (TKI) - SPICI

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: cad7c5d0efc2cd5d2ede912349bc165eb284caef
First added on: Mar 21, 2025